121 related articles for article (PubMed ID: 9426847)
1. Effect of angiotensin converting enzyme inhibition by perindopril on proteinuria of primary renal diseases.
Nosrati SM; Khwaja S; el-Shahawy M; Massry SG
Am J Nephrol; 1997; 17(6):511-7. PubMed ID: 9426847
[TBL] [Abstract][Full Text] [Related]
2. Passive Heymann nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury.
Zoja C; Corna D; Bruzzi I; Foglieni C; Bertani T; Remuzzi G; Benigni A
Exp Nephrol; 1996; 4(4):213-21. PubMed ID: 8983642
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic safety of perindopril in the treatment of mild hypertension with concomitant nephropathy.
Bönner G; Lederle RM; Scholze J; Stumpe KO
Arzneimittelforschung; 1993 Aug; 43(8):852-5. PubMed ID: 8216441
[TBL] [Abstract][Full Text] [Related]
4. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
Matsuda H; Hayashi K; Saruta T
J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
[TBL] [Abstract][Full Text] [Related]
5. A new trial of the efficacy, tolerability, and safety of angiotensin-converting enzyme inhibition in mild systemic hypertension with concomitant diseases and therapies. Perindopril Therapeutic Safety Study Group (PUTS).
Stumpe KO; Overlack A
Am J Cardiol; 1993 Jun; 71(17):32E-37E. PubMed ID: 8328365
[TBL] [Abstract][Full Text] [Related]
6. [Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis].
Iimura O; Kusano E; Tanba K; Yanagiba S; Amemiya M; Ando Y; Honma S; Muto S; Asano Y
Nihon Jinzo Gakkai Shi; 2003 Jul; 45(5):439-44. PubMed ID: 14509219
[TBL] [Abstract][Full Text] [Related]
7. Management of moderate to severe hypertension and proteinuria by nifedipine retard and perindopril after renal transplantation.
Grekas D; Dioudis C; Kalevrosoglou I; Papoulidou F; Goutsaridis N; Alivanis P; Tourkantonis A
Clin Nephrol; 1995 Nov; 44(5):299-302. PubMed ID: 8605709
[TBL] [Abstract][Full Text] [Related]
8. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
Kanno Y; Takenaka T; Nakamura T; Suzuki H
Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
[TBL] [Abstract][Full Text] [Related]
9. Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease.
Gansevoort RT; de Zeeuw D; de Jong PE
Am J Kidney Dis; 1993 Jul; 22(1):202-6. PubMed ID: 8322784
[TBL] [Abstract][Full Text] [Related]
10. Differential efficacy of perindopril and enalapril in experimental diabetic nephropathy.
Duggan KA; Hodge G; Makarious MM; Charlesworth JA
Clin Exp Pharmacol Physiol; 1996; 23(6-7):608-10. PubMed ID: 8800600
[TBL] [Abstract][Full Text] [Related]
11. Long-term reduction of microalbuminuria after 3 years of angiotensin-converting enzyme inhibition by perindopril in hypertensive insulin-treated diabetic patients.
Hermans MP; Brichard SM; Colin I; Borgies P; Ketelslegers JM; Lambert AE
Am J Med; 1992 Apr; 92(4B):102S-107S. PubMed ID: 1580274
[TBL] [Abstract][Full Text] [Related]
12. ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. The Perindopril Therapeutic Safety Collaborative Research Group.
Overlack A; Adamczak M; Bachmann W; Bönner G; Bretzel RG; Derichs R; Krone W; Lederle RM; Reimann HJ; Zschiedrich H
Am J Med; 1994 Aug; 97(2):126-34. PubMed ID: 8059778
[TBL] [Abstract][Full Text] [Related]
13. Value of angiotensin converting enzyme inhibitors in the elderly: the example of perindopril.
Forette F; McClaran J; Delesalle MC; Hervy MP; Bouchacourt P; Henry-Amar M; Santoni JP
Clin Exp Hypertens A; 1989; 11 Suppl 2():587-603. PubMed ID: 2691131
[TBL] [Abstract][Full Text] [Related]
14. [Long-term decrease of microalbuminuria after one year of treatment with perindopril in hypertensive diabetic patients].
Brichard SM; Santoni JP; Thomas JR; Van de Voorde K; Ketelslegers JM; Lambert AE
Ann Cardiol Angeiol (Paris); 1990 Oct; 39(8):495-9. PubMed ID: 2281920
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.
Jafar TH; Schmid CH; Landa M; Giatras I; Toto R; Remuzzi G; Maschio G; Brenner BM; Kamper A; Zucchelli P; Becker G; Himmelmann A; Bannister K; Landais P; Shahinfar S; de Jong PE; de Zeeuw D; Lau J; Levey AS
Ann Intern Med; 2001 Jul; 135(2):73-87. PubMed ID: 11453706
[TBL] [Abstract][Full Text] [Related]
16. Long term reduction of microalbuminuria after 1 year of angiotensin converting enzyme inhibition by perindopril in hypertensive insulin-treated diabetic patients.
Brichard SM; Santoni JP; Thomas JR; van de Voorde K; Ketelslegers JM; Lambert AE
Diabete Metab; 1990; 16(1):30-6. PubMed ID: 2185055
[TBL] [Abstract][Full Text] [Related]
17. A double-blind trial of perindopril and nitrendipine in incipient diabetic nephropathy.
Kopf D; Schmitz H; Beyer J; Frank M; Bockisch A; Lehnert H
Diabetes Nutr Metab; 2001 Oct; 14(5):245-52. PubMed ID: 11806464
[TBL] [Abstract][Full Text] [Related]
18. Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor.
Keilani T; Schlueter WA; Levin ML; Batlle DC
Ann Intern Med; 1993 Feb; 118(4):246-54. PubMed ID: 8420442
[TBL] [Abstract][Full Text] [Related]
19. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.
Jafar TH; Stark PC; Schmid CH; Landa M; Maschio G; Marcantoni C; de Jong PE; de Zeeuw D; Shahinfar S; Ruggenenti P; Remuzzi G; Levey AS;
Kidney Int; 2001 Sep; 60(3):1131-40. PubMed ID: 11532109
[TBL] [Abstract][Full Text] [Related]
20. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy.
Kim MJ; Song JH; Suh JH; Lee SW; Kim GA
Yonsei Med J; 2003 Jun; 44(3):463-72. PubMed ID: 12833584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
